Windlas Biotech Ltd incorporated in 2001, is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive Strengths
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
Windlas Biotech Limited IPO Tentative Timetable
| Particular | Date |
| IPO Open Date | 04 Aug 2021 |
| IPO Close Date | 06 Aug 2021 |
| Allotment Date | 11 Aug 2021 |
| IPO Listing Date | 17 Aug 2021 |
Windlas Biotech Limited IPO Details
| Issue Type | Book Built Issue IPO |
| Face Value | Rs. 5 Per Equity Share |
| IPO Price | Rs. 448 to Rs. 460 Per Equity Share |
| Market Lot | 30 Share |
| NSE Symbol | |
| BSE Symbol | |
| ISIN Code | |
| Listing At | NSE, & BSE |
| Issue Size | Approx. Rs. 401 Crore. |
Windlas Biotech Limited IPO Lot Size
| Application | Lots | Shares | Amount |
| Minimum | 1 | 30 | Rs. 13800 |
| Maximum | 14 | 420 | Rs. 193200 |
Windlas Biotech Limited IPO Allotment Status
Click Here To Check IPO Allotment Status Windlas Biotech Limited IPO
Click Here To Get ASBA Forms Windlas Biotech Limited IPO
Company Financials:
| Particular | 31 March 2021 | 31 March 2020 | 31 March 2019 |
| Total Assets | 2961.23 | 3384.88 | 2981.80 |
| Total Revenue | 4306.95 | 3313.39 | 3115.25 |
| Profit After Tax | 155.70 | 162.13 | 638.22 |
Company Promoters:
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters.
Objects of this Issue:
The net IPO proceeds will be used for the following purposes;
- To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of company’s borrowings.
- General corporate purposes.
Registrar & Company Details
| Company Contact Information | IPO Registrar |
| Windlas Biotech Limited 40/1, Mohabewala Industrial Area, Dehradun, 248110 Phone: +91 135 6608000 Email: grievance@windlasbiotech.com Website: http://www.windlasbiotech.com/ | Link Intime India Private Ltd Link Intime India Private Ltd C 101, 247 Park, L.B.S.Marg, Vikhroli (West), Mumbai – 400083 Phone: +91-22-4918 6270 Email: rolex.ipo@linkintime.co.in Website: http://www.linkintime.co.in |
